News

The Lancet2d
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
eDepartment of Medicine, University of California, San Diego, CA, USA fDivision of Gastroenterology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ...
ascopubs.org4d
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small ...
This phase II study demonstrated the efficacy of osimertinib 80 ... ongoing with treatment. Fig 1. Flow diagram of study population. EFR, evaluable for response; FAS, full analysis set; LM, ...